What is VRCA's P/E ratio?

Verrica Pharmaceuticals Inc (VRCA) currently trades at a P/E ratio of 442.10.

Verrica Pharmaceuticals Inc reports a Return on Equity (ROE) of -111.03%.

What is VRCA's dividend yield?

Verrica Pharmaceuticals Inc offers a dividend yield of 0.00%.

What is VRCA's Quality Score?

Our AI rates VRCA's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy VRCA?

Our AI Timing Score for VRCA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does VRCA belong to?

Verrica Pharmaceuticals Inc is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

Verrica Pharmaceuticals Inc (VRCA) Stock Price

Stock Check Daily update data at 8:30 AM
(Price: 2026-08-04 | FS: 2026-03-31)

VRCA AI Analysis Summary

Our AI summary for VRCA: Verrica Pharmaceuticals Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 442.10, ROE of -111.03%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

VRCA

Verrica Pharmaceuticals Inc

US:NASDAQ STOCK Healthcare >> Biotechnology News 98

USD 5.41

0.16 (3.05%) Day Change

Watchlist Portfolio Compare Chart

442.10

P/E

0.05

D/E

-111.0%

ROE

-46.0%

ROA

0.00%

Div Yield

75.57

PEG

VERRICA PHARMACEUTICALS INC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 5.41 Price 0.16 (3.05%) Day Change	NEWS SCORE: 98

VRCA, the overall quality is not good ( Quality = 46) and the timing to buy is ...(Sign In to See)...

Loading chart...

46 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: P/E ratio is relatively high
ROE is relatively low.
ROA is relatively low.
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...

Quality Factors

48%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	98
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	5.41
PBV / Sector	5.62 / 44,022.72
Earning Per Share	-1.07

PE / Sector	442.10 / 19.17
PEG or PE/Growth / Sector	75.57 / 1.24
Average 1M Daily Value	0.17 M GREAT
Average 1W Daily Value	0.10 M GREAT

Timing Factors

28%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

64%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-47.97 / 98.24
NPM Average (%) / Sector	-537.80 / -1,697.63
NPM Change Average (%) / Sector	65.01 / 5,097.97 GREAT
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-45.96 / 185,260.96
ROA Average (%) / Sector	-72.45 / 36,684.70
ROA Change Average (%) / Sector	17.54 / 422,221.66 GOOD
ROE (%) / Sector	-111.03 / 243,762.23
ROE Average (%) / Sector	38.64 / 48,758.47 GREAT
ROE Change Average (%) / Sector	17.35 / 424,968.10 GOOD
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -0.49

Registration Details

Analyze Date	2026-08-05 08:01:03
Symbol	VRCA
Name	VERRICA PHARMACEUTICALS INC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	17.18 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	90.19 / 9,586.08

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 44 West Gay Street, West Chester, PA, United States, 19380

Phone: 484 453 3300

Website: https://www.verrica.com

Employees: 76

Sector: Healthcare >> Biotechnology

Description: Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.